Jump to: navigation, search

{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 411355479 | IUPAC_name = 8,8'-{Carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]}di(1,3,5-naphthalenetrisulfonic acid) | image = Suramin.png | image2 = Suramin_sf.gif

| tradename = Antrypol, 309 F or 309 Fourneau, Bayer 205, Moranyl, Naganin, Naganine | pregnancy_category = | legal_status = not approved by the US FDA | routes_of_administration = injection

| bioavailability = | metabolism = | excretion =

| CASNo_Ref =  ☑Y | CAS_number_Ref =  ☑Y | CAS_number = 145-63-1 | ATC_prefix = P01 | ATC_suffix = CX02 | ATC_supplemental = Template:ATCvet | PubChem = 5361 | IUPHAR_ligand = 1728 | DrugBank_Ref =  ☒N | DrugBank = DB04786 | ChemSpiderID_Ref =  ☑Y | ChemSpiderID = 5168 | UNII_Ref =  ☑Y | UNII = 6032D45BEM | KEGG_Ref =  ☒N | KEGG = C07974 | ChEBI_Ref =  ☒N | ChEBI = 45906 | ChEMBL_Ref =  ☑Y | ChEMBL = 265502

| C=51 | H=40 | N=6 | O=23 | S=6 

| molecular_weight = 1297.29 | smiles = O=C(Nc1cc(ccc1C)C(=O)Nc3c2c(cc(cc2c(cc3)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)c8cccc(NC(=O)Nc7cc(C(=O)Nc6cc(C(=O)Nc5c4c(cc(cc4c(cc5)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)ccc6C)ccc7)c8 | InChI = 1/C51H40N6O23S6/c1-25-9-11-29(49(60)54-37-13-15-41(83(69,70)71)35-21-33(81(63,64)65)23-43(45(35)37)85(75,76)77)19-39(25)56-47(58)27-5-3-7-31(17-27)52-51(62)53-32-8-4-6-28(18-32)48(59)57-40-20-30(12-10-26(40)2)50(61)55-38-14-16-42(84(72,73)74)36-22-34(82(66,67)68)24-44(46(36)38)86(78,79)80/h3-24H,1-2H3,(H,54,60)(H,55,61)(H,56,58)(H,57,59)(H2,52,53,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)(H,78,79,80) | InChIKey = FIAFUQMPZJWCLV-UHFFFAOYAG | StdInChI_Ref =  ☑Y | StdInChI = 1S/C51H40N6O23S6/c1-25-9-11-29(49(60)54-37-13-15-41(83(69,70)71)35-21-33(81(63,64)65)23-43(45(35)37)85(75,76)77)19-39(25)56-47(58)27-5-3-7-31(17-27)52-51(62)53-32-8-4-6-28(18-32)48(59)57-40-20-30(12-10-26(40)2)50(61)55-38-14-16-42(84(72,73)74)36-22-34(82(66,67)68)24-44(46(36)38)86(78,79)80/h3-24H,1-2H3,(H,54,60)(H,55,61)(H,56,58)(H,57,59)(H2,52,53,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)(H,78,79,80) | StdInChIKey_Ref =  ☑Y | StdInChIKey = FIAFUQMPZJWCLV-UHFFFAOYSA-N }}

WikiDoc Resources for Suramin


Most recent articles on Suramin

Most cited articles on Suramin

Review articles on Suramin

Articles on Suramin in N Eng J Med, Lancet, BMJ


Powerpoint slides on Suramin

Images of Suramin

Photos of Suramin

Podcasts & MP3s on Suramin

Videos on Suramin

Evidence Based Medicine

Cochrane Collaboration on Suramin

Bandolier on Suramin

TRIP on Suramin

Clinical Trials

Ongoing Trials on Suramin at Clinical

Trial results on Suramin

Clinical Trials on Suramin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Suramin

NICE Guidance on Suramin


FDA on Suramin

CDC on Suramin


Books on Suramin


Suramin in the news

Be alerted to news on Suramin

News trends on Suramin


Blogs on Suramin


Definitions of Suramin

Patient Resources / Community

Patient resources on Suramin

Discussion groups on Suramin

Patient Handouts on Suramin

Directions to Hospitals Treating Suramin

Risk calculators and risk factors for Suramin

Healthcare Provider Resources

Symptoms of Suramin

Causes & Risk Factors for Suramin

Diagnostic studies for Suramin

Treatment of Suramin

Continuing Medical Education (CME)

CME Programs on Suramin


Suramin en Espanol

Suramin en Francais


Suramin in the Marketplace

Patents on Suramin

Experimental / Informatics

List of terms related to Suramin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]


Suramin is an antimicrobial drug developed by Oskar Dressel and Richard Kothe of Bayer, Germany in 1916, and is still sold by Bayer under the brand name Germanin. The formula of suramin was kept secret by Bayer for commercial reasons, however, it was elucidated and published in 1924 by Ernest Fourneau and his team of the Pasteur Institute.[1]

It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.[2]

Medical uses


It is used for treatment of human sleeping sickness caused by trypanosomes.[3]


It has been used in the treatment of onchocerciasis.[4]


It has been investigated as treatment for prostate cancer.[5]

Also, suramin as treatment for autism is being evaluated[6] and there are promising results in adult mice.[7][8]

Adverse reactions

The most frequent adverse reactions are nausea and vomiting. About 90% of patients will get an urticarial rash that disappears in a few days without needing to stop treatment. There is a greater than 50% chance of adrenal cortical damage, but only a smaller proportion will require lifelong corticosteroid replacement. It is common for patients to get a tingling or crawling sensation of the skin with suramin. Suramin will cause clouding of the urine which is harmless: patients should be warned of this to avoid them becoming alarmed.

Kidney damage and exfoliative dermatitis occur less commonly.

Suramin has been applied clinically to HIV/AIDS patients resulting in a significant number of fatal occurrences and as a result the application of this molecule was abandoned for this condition.[9]


The molecular formula of suramin is C51H40N6O23S6. It is a symmetric molecule in the center of which lies a urea (NH–CO–NH) functional group. Suramin contains eight benzene rings, four of which are fused in pairs (naphthalene), four amide groups (in addition to the urea) and six sulfonic acid groups. When given as drug, it is usually as the sodium sulfonate, with six sodium ions on the sulfonate groups rather than hydrogens.


According to the National Cancer Institute there are no active clinical trials.[10]

Suramin is also used in research as a broad-spectrum antagonist of P2 receptors[11][12] and agonist of Ryanodine receptors.[13]

Its effect on telomerase has been investigated.[14]

It may have some activity against RNA viruses.[15]

In addition to antagonism of P2 receptors, Suramin inhibits the activation of heterotrimeric G proteins in a variety of other GPCRs with varying potency. It prevents the association of heteromeric G proteins and therefore the receptors guanine exchange functionality (GEF). With this blockade the GDP will not release from the Gα subunit so it can not be replaced by a GTP and become activated. This has the effect of blocking downstream G protein mediated signaling of various GPCR proteins including rhodopsin, the A1 adenosine receptor, and the D2 dopamine receptor.[16]


  1. E. Fourneau, J. and Th. Tréfouël and J. Vallée (1924). "Sur une nouvelle série de médicaments trypanocides", C. R. Séances Acad. Sci. 178: 675.)
  2. "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
  3. Darsaud A, Chevrier C, Bourdon L, Dumas M, Buguet A, Bouteille B (January 2004). "Megazol combined with suramin improves a new diagnosis index of the early meningo-encephalitic phase of experimental African trypanosomiasis". Trop. Med. Int. Health. 9 (1): 83–91. doi:10.1046/j.1365-3156.2003.01154.x. PMID 14728611.
  4. Anderson J, Fuglsang H (July 1978). "Further studies on the treatment of ocular onchocerciasis with diethylcarbamazine and suramin". Br J Ophthalmol. 62 (7): 450–7. doi:10.1136/bjo.62.7.450. PMC 1043255. PMID 678497.
  5. Ahles TA, Herndon JE, Small EJ; et al. (November 2004). "Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480". Cancer. 101 (10): 2202–8. doi:10.1002/cncr.20655. PMID 15484217.
  9. . PMID 3548350. Missing or empty |title= (help)
  10. Completed and closed clinical trials are listed here: [1]
  11. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA. (September 2006). "International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy". Pharmacol Rev. 58 (3): 281–341. doi:10.1124/pr.58.3.3. PMC 3471216. PMID 16968944.
  12. Khakh BS, Burnstock G, Kennedy C, King BF, North RA, Séguéla P, Voigt M, Humphrey PP. (March 2001). "International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits". Pharmacol Rev. 53 (1): 107–118. PMID 11171941.
  13. Wolner I, Kassack MU, Ullmann H, Karel A, Hohenegger M (October 2005). "Use-dependent inhibition of the skeletal muscle ryanodine receptor by the suramin analogue NF676". Br. J. Pharmacol. 146 (4): 525–33. doi:10.1038/sj.bjp.0706359. PMC 1751178. PMID 16056233.
  14. Erguven M, Akev N, Ozdemir A, Karabulut E, Bilir A (August 2008). "The inhibitory effect of suramin on telomerase activity and spheroid growth of C6 glioma cells". Med. Sci. Monit. 14 (8): BR165–73. PMID 18667993.
  15. Mastrangelo E, Pezzullo M, Tarantino D, Petazzi R, Germani F, Kramer D, Robel I, Rohayem J, Bolognesi M, Milani M (2012) Structure-based inhibition of norovirus RNA-dependent RNA-polymerases. J Mol Biol
  16. Beindl W, Mitterauer T, Hohenegger M, Ijzerman AP, Nanoff C, Freissmuth M. (August 1996). "Inhibition of receptor/G protein coupling by suramin analogues". ol. Pharmacology. 50 (2): 415–23. PMID 8700151.

External links